PARTNER cohort B: Clinical events at 3 years follow-up in patients with

Background: Percutaneous aortic valve implantation (TAVI) is the treatment of choice for patients with severe aortic stenosis considered inoperable according to clinical outcomes at 12 months as reported in the PARTNER study, which demonstrated a reduction in mortality and an improvement in the quality of life for patients. However, the long term benefit of this<a href="https://solaci.org/en/2015/06/24/partner-cohort-b-clinical-events-at-3-years-follow-up-in-patients-with/" title="Read more" >...</a>

PARTNER cohort A at three years, the benefit continues

The PARTNER Cohort A randomized 699 elderly patients, (mean age 84.1), with severe aortic stenosis for TAVI or conventional surgery in 26 centers. The group of patients who received TAVI was divided into two groups: trans-femoral procedure, (244 patients), or trans-apical procedure, (104 patients). After one year mortality was similar but stroke and transient ischemic<a href="https://solaci.org/en/2015/06/24/partner-cohort-a-at-three-years-the-benefit-continues/" title="Read more" >...</a>

PARTNER 2: Edwards SAPIEN XT is even better. Results for PARTNER II, cohort B.

In the PARTNER 1 study, patients with inoperable severe aortic stenosis treated with an aortic valve prosthesis balloon-expandable Edwards-SAPIEN showed a mortality reduction compared with standard treatment. However, the Edwards SAPIEN device is associated with peri-procedural complications. The new generation of Edwards SAPIEN XT prosthesis incorporates significant improvements in the profile of the delivery system,<a href="https://solaci.org/en/2015/06/24/partner-2-edwards-sapien-xt-is-even-better-results-for-partner-ii-cohort-b/" title="Read more" >...</a>

COREVALVE EXTREME RISK: Promising results with CoreValve in very high-risk patients

Percutaneous aortic valve implantation ( TAVI ) recently demonstrated its superiority over medical treatment in patients with severe aortic stenosis and high surgical risk. Furthermore patients receiving TAVI showed a survival surgery equivalent to one year. This study included 471 patients with symptomatic severe aortic stenosis discarded of surgery due  a very high risk. The<a href="https://solaci.org/en/2015/06/24/corevalve-extreme-risk-promising-results-with-corevalve-in-very-high-risk-patients/" title="Read more" >...</a>

Results of the new repositionable and retrievable percutaneous valve system

Original title: Transcatheter Aortic Valve Replacement for Severe Symptomatic Aortic Stenosis Using a Repositionable Valve System. 30-Day Primary Endpoint Results From the REPRISE II Study. Reference: Ian T. Meredith AM et al. J Am Coll Cardiol 2014;64:1339–48. Transcatheter aortic valve replacement (TAVR) showed results comparable to those of surgery in patients at high surgical risk, but complications can<a href="https://solaci.org/en/2015/01/29/results-of-the-new-repositionable-and-retrievable-percutaneous-valve-system/" title="Read more" >...</a>

Worse post TAVI ejection fraction recovery in coronary artery disease patients without revascularization

Original title: Impact of coronary artery disease on left ventricular ejection fraction recovery following transcatheter aortic valve implantation. Reference: Freixa X et al. Catheter Cardiovasc Interv. 2014;Epub ahead of print. This single center study analyzed data form 56 consecutive patients with severe aortic stenosis and LVEF of ≤ 50% undergoing TAVI (transcatheter aortic valve implantation) between March 2006<a href="https://solaci.org/en/2014/10/06/worse-post-tavi-ejection-fraction-recovery-in-coronary-artery-disease-patients-without-revascularization/" title="Read more" >...</a>

Core Valve in high-risk patients, superior to surgical replacement at one year

Original title: Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis. Reference: David H. Adams et al. N Engl J Med. 2014 Mar 29. [Epub ahead of print]. Transcatheter Aortic valve replacement (TAVR) with balloon expandable valve showed survival improvement in inoperable patients and was similar to surgery inoperable high-risk patients. An alternative to the above device is the self-expandable<a href="https://solaci.org/en/2014/04/09/core-valve-in-high-risk-patients-superior-to-surgical-replacement-at-one-year/" title="Read more" >...</a>

Predilation with smaller valvuloplasty balloon diameter could reduce the need for permanent pacemaker after CoreValve

Original title: Reduction of pacemaker implantation rates alter CoreValve implantation by moderate predilatation Reference: Philipp Lange, et al. EuroIntervention 2014;9:1151-1159 Aortic valve implantation has been proven a valid strategy to treat high risk patients. The CoreValve self-expanding transcatheter aortic valve is associated with a relatively high rate of permanent pacemaker implantation and, until now, no efforts have been<a href="https://solaci.org/en/2014/03/05/predilation-with-smaller-valvuloplasty-balloon-diameter-could-reduce-the-need-for-permanent-pacemaker-after-corevalve/" title="Read more" >...</a>

El Impella otorga seguridad en la ATC del TCI no protegido de alto riesgo

Patients with CABG History and new N-ST ACS: Routine Invasive Strategy?

Multiple studies support the use of an early invasive approach in high risk patients with non-ST elevation acute coronary syndrome (NST ACS). This benefit of an invasive strategy over the expected management has been shown in randomized studies and meta-analysis. Patients with a history of cardiac artery bypass graft (CABG) represent approximately 10% of ACS<a href="https://solaci.org/en/2024/06/10/patients-with-cabg-history-and-new-n-st-acs-routine-invasive-strategy/" title="Read more" >...</a>

ACC 2024 | IVUS-DCB

Drug-coated balloons (DCB) have proven to be effective in the treatment of femoropopliteal pathology, although they entail complications such as recoil, residual stenosis, and dissection. Their outcomes could be improved through proper and enhanced vessel preparation, both before and after the procedure. Intravascular ultrasound (IVUS) offers the advantage of characterizing plaque and assessing vessel diameter.<a href="https://solaci.org/en/2024/04/17/acc-2024-ivus-dcb-3/" title="Read more" >...</a>